Canada Markets close in 5 hrs 50 mins

Nemaura Medical Inc. (NMRD)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
3.6066+0.0566 (+1.59%)
As of 9:49AM EDT. Market open.
Sign in to post a message.
  • j
    jeff
    Awesome stock suggested to buy this morning. I guess they missed that one
  • J
    Jared
    $CRMD conversation
    Hi everyone. Im long here& mostly a lurker, but was curious...
    Anyone following $NMRD and care to give their opinion?
  • K
    Kevin
    This is a significant announcement. A non dilutive $8m facility from existing shareholders without any warrants or options attached is an amazing deal by the management.

    It shows a real belief by those providing the cash that this company can fully commercialise their products.

    I don’t think we’ll see major upside movement until orders start coming in but once they do, I think we’ll see a strong re-rating.
  • D
    Donna
    Diabetic monitor without a needle ! Worldwide sales could be ENORMOUS.
  • G
    George
    Figures the second I buy, it drops 10% The story of my life
  • M
    MILENA
    Whats happening? Anyone have a clue. I bought at $14 so jave lost a bit. Can anyone tell me what I should do if you have the inside scoop?
  • S
    SMAC-dolla
    Abbot buyout
  • W
    William
    From Neumara. Note bullet point #5...it's really going to happen any day now.

    Product Launch Timelines
    Non-invasive, Flexible and Affordable
    ❖ SugarBEAT® commercial launch expected Q4 2018 in UK, followed in
    Q1 2019 by major European countries
    ❖ Initial focus on self-pay market
    ❖ SugarBEAT® completed 525 patient day (75 patients x 7 days) European
    Trial in Q4 217
    ❖ Published summary of results in January 2018
    ❖ CE Mark approval expected in Q3 2018
    ❖ CE Mark granted Q1 2016 on predecessor version (wrist-watch format)
    ❖ FDA clinical program commenced in Q2 2018 to support anticipated FDA
    submission in Q1 2019
  • K
    Kevin
    The business appears near to producing revenue for the first time in its history.

    The reception and take up will be the make or break of this stock.
  • m
    mike
    If you want to know how much NMRD paid to have the press release done this morning - here it is. The PR was written for NMRD exclusively - it wasn't really news.

    FinancialBuzz.com has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com has signed an initial two week agreement for ten thousand restricted shares.
  • W
    William
    Strange quirk. Price was at 2.70 at 10:40 this morning. At 1pm there were 30 straight buys and NO selling, yet the stock dropped to 2.60. How can that be?
  • h
    hemal
    $5.00 by fri
  • D
    Donna
    SugarBEAT® is anticipated to launch in the UK in the coming months, and is intended to be marketed to all categories of diabetics, including Type 1, Type 2 and pre-diabetics.
  • m
    mike
    FinancialBuzz.com has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com has signed an initial two week agreement for ten thousand restricted shares.
  • B
    BAGHOLDER HUMPER
    Everybody NEEDS to read THIS:

    Read:

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6412701/

    Look for the table "List of commercial devices for non-invasive glucose monitoring never released or withdrawn" and check out the two devices at the TOP of the list.

    Guess WHAT! "Sugarbeat" by ANY other name is a "Glucowatch" and/or a "Glucall"!

    And I GUARANTEE that "sugarbeat" will be on that list before much LONGER!

    'Nuff said!
    Current glucose monitoring methods for the ever-increasing number of diabetic people around the world are invasive, painful, time-consuming, and a constant burden for the household budget. The non-invasive glucose monitoring technology overcomes thes
    Current glucose monitoring methods for the ever-increasing number of diabetic people around the world are invasive, painful, time-consuming, and a constant burden for the household budget. The non-invasive glucose monitoring technology overcomes thes
    www.ncbi.nlm.nih.gov
  • c
    chomchom
    published positive data and fall 38 percent . Funny
  • R
    Randy
    heading for Splashdown somewhere around $ 2.30
  • M
    M
    It is time to buy. England launch is this month.
  • M
    Marcus
    The company will be delisted soon from nasdaq; also they ran out of cash so I do not know how much longer they will avoid bankruptcy.